Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $102,467.67 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 5,627 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $18.21, for a total value of $102,467.67. Following the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,646,914.55. This represents a 3.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.23, for a total value of $116,945.45.
• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total transaction of $332,405.68.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total transaction of $118,359.38.

Bicara Therapeutics Stock Performance

BCAX stock opened at $17.78 on Friday. The stock has a market capitalization of $970.97 million and a PE ratio of -5.61. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $28.09. The company has a fifty day moving average of $12.51 and a 200-day moving average of $11.87.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. Equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Piper Sandler assumed coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, August 12th. Finally, HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.86.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its position in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares in the last quarter. Vestal Point Capital LP raised its position in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after acquiring an additional 2,231,025 shares during the last quarter. Bank of America Corp DE raised its position in Bicara Therapeutics by 2,351.0% during the second quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after acquiring an additional 432,818 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in Bicara Therapeutics during the second quarter worth about $149,000. Finally, Jane Street Group LLC acquired a new position in Bicara Therapeutics during the second quarter worth about $266,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.